Cycle Pharmaceuticals, Inc. (Cycle) has announced the successful acquisition of Banner Life Sciences, LLC (Banner), which encompasses its BAFIERTAM® (monomethyl fumarate) product for treating relapsing forms of multiple sclerosis (MS) in adults, as approved by the US Food and Drug Administration (FDA). MS impacts roughly 1 million individuals in the US, with about 200 new cases diagnosed weekly.
Approximately 85% of these diagnoses are the relapsing-remitting type, and without intervention, around 50% of them advance to the more severe secondary-progressive type within a decade. BAFIERTAM will serve as Cycle’s second branded therapy for the treatment of MS, in addition to TASCENSO ODT (fingolimod). Similar to TASCENSO, BAFIERTAM patients will gain from Cycle's leading hub program, Cycle Vita. Patients using BAFIERTAM will continue to receive support from Banner’s established network throughout the transition period.
“We are delighted to strengthen Cycle’s offer to the MS community by adding BAFIERTAM to our MS product portfolio. We will be able to support more patients via our best-in-class patient support hub Cycle Vita*, as well as giving patients full confidence in the medicines they are using to manage their MS,” says James Harrison – CEO of Cycle.
, CDSCO.jpg)
